[This Week's IPO] February First Week Demand Forecast and Subscription Schedule

In the first week of this month (February), LK Chem and Winners will conduct demand forecasting targeting institutional investors. ISTE, Dongbang Medical, Orum Therapeutics, and Dongguk Life Science are preparing for general subscription.

◆LK Chem= Since its establishment in November 2007, the company has steadily grown by focusing on the development and mass production of advanced materials based on its proprietary technology accumulated in the semiconductor and electronic materials fields. Currently, the company develops and produces CP ligands, PCP ligands, and DIS precursors, which are core raw materials for High-k and Low-k materials, playing an essential role in semiconductor deposition processes.

The company plans to offer a total of 1 million shares. The expected public offering price ranges from 18,000 to 21,000 KRW, with a total public offering amount of 18 billion to 21 billion KRW. Demand forecasting will be conducted over five days from the 4th to the 10th, followed by general subscription over two days on the 13th and 14th, aiming for a KOSDAQ listing within February. Shin Young Securities is the lead underwriter.

◆Winners= Since its establishment in 2004, Winners has expanded its business through the development and supply of wiring devices, and recently has been broadening its business areas by discovering new growth engines such as battery-free switches and electric vehicle chargers applying energy harvesting technology.

The total number of shares offered is 1.7 million, with a desired public offering price range of 7,500 to 8,500 KRW, and a total public offering amount of 12.75 billion to 14.45 billion KRW. The public offering price will be finalized through demand forecasting targeting institutional investors from the 4th to the 10th, followed by general subscription over two days on the 13th and 14th. Mirae Asset Securities is the lead underwriter.

◆ISTE= The public offering price was fixed at the upper limit of the desired price, 11,400 KRW. A total of 2,074 companies participated in the demand forecasting, recording a competition rate of 1,148.16 to 1. General subscription will be conducted over two days on the 3rd and 4th. The scheduled listing date is the 12th. KB Securities is the lead underwriter.

Established in 2013, ISTE is a specialized company developing and mass-producing semiconductor equipment, focusing on future growth by successfully developing PECVD, a core semiconductor process equipment. Based on professional research personnel and national projects for PECVD, the company succeeded in developing SiCN PECVD equipment in 2021.

◆Dongbang Medical= The public offering price was fixed at the upper limit of the desired price, 10,500 KRW. A total of 2,241 institutions participated in the demand forecasting, recording a competition rate of 910.14 to 1. General subscription for individual investors will be conducted on the 3rd and 4th, with a planned KOSDAQ listing on the 13th. NH Investment & Securities is the lead underwriter.

Dongbang Medical possesses both traditional Korean medical device products such as acupuncture needles and cupping cups, and aesthetic medical device products including fillers, absorbable sutures, and various special needles. The company has advanced its core needle processing technology and has achieved results in manufacturing various special needles such as cannulas used during filler injections based on this technology.

◆Orum Therapeutics= The company plans to offer a total of 2.5 million shares. The desired public offering price range is 24,000 to 30,000 KRW. General subscription will be accepted on the 4th and 5th. Korea Investment & Securities is the lead underwriter.

Orum Therapeutics is a leading bio company in the antibody-drug conjugate (ADC) field based on the dual precision targeted protein degradation approach ‘TPD²®’. ADC is a next-generation modality that selectively delivers targeted protein degraders (TPD) to target cells through antibodies and degrades target proteins inside cells.

◆Dongguk Life Science= The public offering price was fixed at 9,000 KRW, which is lower than the lower limit of the desired price band. General subscription will be conducted on the 5th and 6th. NH Investment & Securities and KB Securities are the lead underwriters.

Established in May 2017, Dongguk Life Science currently holds the number one market share in the domestic contrast agent market, achieving a dominant market position. The contrast agents, in which the company has a strong competitive advantage, have the benefit of enabling faster and more accurate diagnosis by making diagnostic areas such as organs, blood vessels, and tissues clearer in imaging diagnostics like CT and MRI.